Format

Send to

Choose Destination
Am J Cardiol. 2018 Aug 16. pii: S0002-9149(18)31653-9. doi: 10.1016/j.amjcard.2018.08.020. [Epub ahead of print]

Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.

Author information

1
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart & Vascular Center, Houston, Texas.
2
Brigham and Women's Hospital, Boston, Massachusetts.
3
Cardiometabolic Trials, Baim Institute for Clinical Research, Boston, Massachusetts.
4
Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon.
5
Department of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Abstract

This CME-accredited CME Snapshot seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin or kexin type 9 (PCSK9). (Online access: https://lipidsnapshotcme.elsevierresource.com/.).

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center